Completed PHASE1 INTERVENTIONAL NCT00002960

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd/p53) Administered by Single Intraperitoneal Instillation

Sponsor: Merck Sharp & Dohme LLC

Conditions Fallopian Tube Cancer Metastatic Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer

Interventions recombinant adenovirus-p53 SCH-58500

Updated 6 times since 2017 Last updated: Feb 3, 2016 Started: Jun 30, 1999 Primary completion: Jul 31, 2000 Completion: Jul 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002960, this PHASE1 trial focuses on Fallopian Tube Cancer and Metastatic Cancer and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.